AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
== History == The predecessor of modern countercurrent chromatography theory and practice was countercurrent distribution (CCD). The theory of CCD was described in the 1930s by Randall and Longtin. Archer Martin and Richard Laurence Millington Synge developed the methodology further during the 1940s. Finally, Lyman C. Craig introduced the Craig countercurrent distribution apparatus in 1944 which made CCD practical for laboratory work. CCD was used to separate a wide variety of useful compounds for several decades.
Other nanoparticles are polymer-based, meaning they are made from a natural polymer such as polylactic acid (PLA), polyglycolide (PLG), polylactide-co-glycolide (PLGA), and polycyanoacrylate (PCA). Some studies have found that polymeric nanoparticles may provide better results for drug delivery relative to lipid-based nanoparticles because they may increase the stability of the drugs or proteins being transported. Polymeric nanoparticles may also contain beneficial controlled release mechanisms.
Robinson, running unopposed, became the Republican nominee for Oregon's 4th congressional district, to again face incumbent DeFazio, who had defeated Robinson's son Matthew in a landslide in the Democratic primary. In the general election, DeFazio defeated Robinson by 212,866 votes (59.1%) to 140,549 (39%).
==== Sodium ==== Cortisol promotes sodium absorption through the small intestine of mammals. Sodium depletion, however, does not affect cortisol levels so cortisol cannot be used to regulate serum sodium. Cortisol's original purpose may have been sodium transport. This hypothesis is supported by the fact that freshwater fish use cortisol to stimulate sodium inward, while saltwater fish have a cortisol-based system for expelling excess sodium.
Sources: en.wikipedia.org
=== Singles/EPs/demos === "Children Break" (1988) Barging Into the Presence of God EP (September 1989) UK Indie No. 3 UK No. 135 Half-Life EP (October 1990), 12" contains a bonus spoken-word track "Colour of the Sky" UK No. 86 "Kinky Love" (1991) (12" issued as Flesh Balloon EP) (June 1991) UK No. 72 "Porpoise" (1991) "Throwing Back the Apple" (May 1992) UK No. 93 Fine Friend EP (August 1994) "Fine Friend" (1994), US promo including "One Blue Hill" live acoustic @ KCRW "Angel (Will You Be My)" (1995), US promo
=== Evaluating approaches to AI === No established unifying theory or paradigm has guided AI research for most of its history. The unprecedented success of statistical machine learning in the 2010s eclipsed all other approaches (so much so that some sources, especially in the business world, use the term "artificial intelligence" to mean "machine learning with neural networks"). This approach is mostly sub-symbolic, soft and narrow.
Further, while defending Mogo from an attack by the Sinestro Corps, the Green Lantern Arisia Rrab explains that Mogo is responsible for guiding Lantern power rings without users to those who can overcome great fear, and says that "without him, the rings are directionless".
Sidestream smoke is smoke which goes into the air directly from a burning cigarette, cigar, or smoking pipe. Sidestream smoke is the main component (around 85%) of second-hand smoke (SHS), also known as Environmental Tobacco Smoke (ETS) or passive smoking. The relative quantity of chemical constituents of sidestream smoke are different from those of directly inhaled ("mainstream") smoke, although their chemical composition is similar. Sidestream smoke has been classified as a Class A carcinogen by the U.S. Environmental Protection Agency.
==== Context ==== The formation of the third cabinet followed the resignation of Mirtha Vásquez on the eve of 31 January 2022. This occurred the day after the resignation of the Minister of the Interior, who resigned citing a “structural problem of corruption” and the impossibility of creating consensus. This decision triggered a political crisis, with the previously supportive Purple Party demanding the formation of a capable government or else the resignation of President Pedro Castillo. The third vice president of the Congress Patricia Chirinos (AvP) announced the filing of a motion of censure against the president, citing the "evident corruption of his government."
Sources: en.wikipedia.org
== Metabolism == In the case of ET/SRTX binding to a receptor and creation of a receptor-ligand complexes in various tissues, a very slow pace of dissociation is observed. In experiments conducted on rats, half-time of SRTX-b in the ileum is about 7 min (with comparison of 2 hours in case of ET-3), while in the cerebellum, the t1/2 values are more than 2–3 hours for both SRTX-b and ET-1, and in case of ET-3, the dissociation rate is negligible. Iodinated SRTX-b binds specifically to preparations of atrial membranes with a maximum binding capacity of 110 fmol per mg of protein and a dissociation constant (KD) of 3–5 nM. SRTX-a, SRTX-b and STRX-c inhibit binding of iodinated SRTX-b in the atrium at mean inhibitory concentrations (IC50) of 30, 25 and 100 nM, respectively. Other binding experiments have also shown that 125I-SRTX-b recognizes sites in a rat cerebellum KD = 3.5 nM and cerebral cortex KD=0.3nM. Furthermore, it has been shown that:
Another rationale for including snake flesh was the widespread belief that snakes contained an antidote to protect themselves against being poisoned by their own venom. Thinking by analogy, Henry Grosmont also thought of theriac as a moral curative, the medicine "to make a man reject the poisonous sin which has entered into his soul". Because the plague, most notably the Black Death, was believed to have been sent by God as a punishment for sin and had its origins in pestilential serpents that poisoned the rivers, theriac was a particularly appropriate remedy or therapeutic. By contrast, Christiane Fabbri argues that theriac, which very frequently contained opium, actually did have palliative effect against pain and reduced coughing and diarrhea.
IC-26 (WIN 1161-3, Methiodone) is an analogue of the opioid analgesic methadone, where the carbonyl group has been replaced by the bioisosteric sulfone group. Human and animal studies suggest that IC-26 is around the same potency as methadone, although other studies have found its activity to be inconsistent between different patients, with consistent opioid activity only being seen at a dose several times that of methadone. IC-26 was assessed for its abuse potential, but despite being found to have similar potential to morphine for development of dependence it was never placed under international control as an illegal drug.
After transplantation, liver biopsy is the best method to monitor the evolution of post-transplant fibrosis, with significant fibrosis or portal hypertension one year after transplantation predicting rapid progression and graft loss and indicating the need for urgent intervention.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.